SCHEMBL2204041

SCHEMBL2204041

CCCN(CCC)CCCCNCc1ccc(CN=Cc2ccccc2)cc1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CXCR4 P61073 1/20 0.41
MAOA P21397 1/20 0.41
CA2 P00918 2/20 0.40
HRH4 Q9H3N8 1/20 0.40
HRH3 Q9Y5N1 1/20 0.40
CHRM2 P08172 1/20 0.40
CA1 P00915 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.39
DRD2 P14416 1/20 0.39
DRD4 P21917 1/20 0.39
DRD3 P35462 1/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
SIGMAR1 Q99720 3/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C19 P33261 1/20 0.38
TMEM97 Q5BJF2 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2202386 0.86 CHRM2 (0.50) CXCR4MAOAHRH4HRH3CHRM2
SCHEMBL2202962 0.85 SCN8A (0.40) CXCR4CA2HRH4HRH3CHRM2
SCHEMBL12509867 0.85 MAOA (0.43) CXCR4MAOAHRH4HRH3CHRM2
SCHEMBL2203351 0.83 ALDH1A1 (0.43) CXCR4CA2CHRM2CA1SMN1; SMN2
SCHEMBL2203380 0.82 CXCR4 (0.39) CXCR4HRH4HRH3CHRM2CA1
SCHEMBL2204056 0.79 CXCR4 (0.54) CXCR4HRH4HRH3CHRM2SMN1; SMN2
SCHEMBL12510185 0.78 HRH4 (0.47) CXCR4MAOAHRH4HRH3CHRM2
SCHEMBL4947145 0.78 CA2 (0.42) CA2CHRM2CA1SMN1; SMN2DRD2
SCHEMBL2201877 0.78 SMN1; SMN2 (0.45) CXCR4HRH4HRH3CHRM2SMN1; SMN2
SCHEMBL12426446 0.77 CXCR4 (0.43) CXCR4HRH4HRH3CHRM2SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722719-B2 Amine compound and use for same KUREHA CORPORATION (JP) 2014-05-13 US disclosed
US-20130245280-A1 AMINE COMPOUND AND USE FOR SAME KUREHA CORPORATION (JP) 2013-09-19 US disclosed
EP-2626349-A1 AMINE COMPOUND AND USE FOR SAME Kureha Corporation (JP) 2013-08-14 EP disclosed
US-7977512-B2 Amine derivative, and production method and use thereof KUREHA CORPORATION (JP) 2011-07-12 US disclosed
US-7977512-B2 Amine derivative, and production method and use thereof KUREHA CORPORATION (JP) 2011-07-12 US disclosed
US-7977512-B2 Amine derivative, and production method and use thereof KUREHA CORPORATION (JP) 2011-07-12 US disclosed
US-20080293951-A1 Amin Derivative, and Production Method and Use Thereof KUREHA CORPORATION 2008-11-27 US disclosed
US-20080293951-A1 Amin Derivative, and Production Method and Use Thereof KUREHA CORPORATION 2008-11-27 US disclosed
US-20080293951-A1 Amin Derivative, and Production Method and Use Thereof KUREHA CORPORATION 2008-11-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130245280-A1 AMINE COMPOUND AND USE FOR SAME SAT1, ALDH7A1, HNMT CXCR4 4194/4885MAOA 83/4885CA2 1210/4885
US-20080293951-A1 Amin Derivative, and Production Method and Use Thereof BCAT2, BCAT1, MRPL9 CXCR4 2546/4885MAOA 632/4885CA2 1761/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.